Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
UnitedHealth Vs. Novo Nordisk: Which Healthcare Giant Fits Your Portfolio?
12:50pm, Tuesday, 19'th Aug 2025
Two healthcare giants, UnitedHealth Group Inc UNH and Novo Nordisk A/S NVO, are duking it out in very different ways for investors' attention. Both stocks have faced heavy losses this year—UNH down
LOS ANGELES, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on be
Why Novo Nordisk Stock Popped Today
11:24am, Tuesday, 19'th Aug 2025
Viking Therapeutics (VKTX -43.03%) stock collapsed in morning trading Tuesday, down more than 40% after reporting mixed results for its GLP-1 weight loss pill VK2735. As Viking shares plummet, however
Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S(NVO)
08:45am, Tuesday, 19'th Aug 2025
NEW YORK , Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
07:37am, Tuesday, 19'th Aug 2025
Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated p
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
07:16am, Tuesday, 19'th Aug 2025
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should be
BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
12:33am, Tuesday, 19'th Aug 2025
Heidelberg, Germany--(Newsfile Corp. - August 19, 2025) - BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with No
Novo Nordisk: Negative Streak Finally Ended
04:42pm, Monday, 18'th Aug 2025
The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended this month. Novo Nordisk faces near-term challenges from semaglutide compou
September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO
04:06pm, Monday, 18'th Aug 2025
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Is Novo Nordisk deal the much-needed catalyst for Goodrx stock?
03:47pm, Monday, 18'th Aug 2025
Goodrx Holdings Inc (NASDAQ: GDRX) closed roughly 50% higher on August 18th after Bagsværd-headquartered Novo Nordisk (NYSE: NVO) announced a GLP-1 partnership with the healthcare platform. According
Novo Nordisk: Market Still Pricing It At Crisis Valuations
02:45pm, Monday, 18'th Aug 2025
Novo Nordisk A/S is facing an unprecedented crisis of confidence as the tumble in its valuations reached extremely fearful levels. Novo remains the global leader in diabetes and obesity drugs, with st
From Doubt To Action: Why I Bought Novo Nordisk After Earnings
01:53pm, Monday, 18'th Aug 2025
Novo Nordisk A/S Q2 earnings were solid, but the guidance disappointed. My investment decision was based on a long-term outlook rather than this single quarter. Novo Nordisk's narrative shifted rapidl
GLP-1 drug Wegovy approved to treat liver disease, what's driving Q2 earnings results
01:47pm, Monday, 18'th Aug 2025
Morning Brief anchor Julie Hyman breaks down the latest market news for August 18, 2025. Novo Nordisk's weight loss drug Wegovy is the first GLP-1 drug approved to treat liver disease.
